Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...
News-Medical.Net on MSN

Study overturns assumptions about PTPN22 risk gene’s role in interferon production

A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...
Seeking Alpha

Amneal Receives U.S. FDA Approval for Iohexol Injection

BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s iohexol injection (300 ...
Medical Dialogues

DoP Shortlists Patented, Unlaunched Drugs for Global Tender Exemption, See Full List

In a move that could significantly reshape India's pharmaceutical procurement landscape, the Department of Pharmaceuticals ...
Nature

Sunitinib versus interferon-α in metastatic RCC

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma. The ...
eLife

Epigenetic Adaptation Drives Monocyte Differentiation into Microglia-Like Cells Upon Engraftment into the Central Nervous System

The authors investigated the epigenetic mechanisms regulating the differentiation of circulating monocytes that infiltrate the CNS and adopt microglia-like characteristics. The work is useful to the ...